SG10201600985XA - Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib - Google Patents

Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib

Info

Publication number
SG10201600985XA
SG10201600985XA SG10201600985XA SG10201600985XA SG10201600985XA SG 10201600985X A SG10201600985X A SG 10201600985XA SG 10201600985X A SG10201600985X A SG 10201600985XA SG 10201600985X A SG10201600985X A SG 10201600985XA SG 10201600985X A SG10201600985X A SG 10201600985XA
Authority
SG
Singapore
Prior art keywords
bortezomib
containing antibodies
antibodies recognizing
combinations containing
recognizing specifically
Prior art date
Application number
SG10201600985XA
Inventor
Jutta Deckert
Pascale Lejeune
Michele F Mayo
Peter U Park
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44168449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201600985X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG10201600985XA publication Critical patent/SG10201600985XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
SG10201600985XA 2010-12-10 2011-12-08 Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib SG10201600985XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10306395 2010-12-10

Publications (1)

Publication Number Publication Date
SG10201600985XA true SG10201600985XA (en) 2016-03-30

Family

ID=44168449

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013044144A SG191059A1 (en) 2010-12-10 2011-12-08 Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
SG10201600985XA SG10201600985XA (en) 2010-12-10 2011-12-08 Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013044144A SG191059A1 (en) 2010-12-10 2011-12-08 Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib

Country Status (41)

Country Link
US (1) US9314522B2 (en)
EP (2) EP2648747B1 (en)
JP (1) JP6177133B2 (en)
KR (1) KR101905208B1 (en)
CN (2) CN103282050B (en)
AR (1) AR084196A1 (en)
AU (1) AU2011340472B2 (en)
BR (1) BR112013014370B1 (en)
CA (1) CA2820382C (en)
CL (1) CL2013001670A1 (en)
CO (1) CO6801634A2 (en)
CR (1) CR20130270A (en)
CY (1) CY1121179T1 (en)
DK (1) DK2648747T3 (en)
DO (1) DOP2013000132A (en)
EA (2) EA026406B1 (en)
EC (1) ECSP13012669A (en)
ES (1) ES2694784T3 (en)
GT (1) GT201300147A (en)
HR (1) HRP20181787T1 (en)
HU (1) HUE039893T2 (en)
IL (1) IL226756B (en)
LT (1) LT2648747T (en)
MA (1) MA34816B1 (en)
MX (1) MX345257B (en)
MY (1) MY165109A (en)
NI (1) NI201300050A (en)
NZ (1) NZ612055A (en)
PE (1) PE20140004A1 (en)
PL (1) PL2648747T3 (en)
PT (1) PT2648747T (en)
RS (1) RS57997B1 (en)
SG (2) SG191059A1 (en)
SI (1) SI2648747T1 (en)
TN (1) TN2013000245A1 (en)
TR (1) TR201816532T4 (en)
TW (1) TWI596116B (en)
UA (1) UA112170C2 (en)
UY (1) UY33791A (en)
WO (1) WO2012076663A1 (en)
ZA (1) ZA201304845B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
ES2617446T3 (en) 2010-09-27 2017-06-19 Morphosys Ag Anti-cd38 and lenalidomide or bortezomib antibody for the treatment of multiple myeloma and nhl
UA112170C2 (en) 2010-12-10 2016-08-10 Санофі ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB
JOP20210044A1 (en) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
AU2013322806C1 (en) 2012-09-25 2018-03-08 Morphosys Ag Combinations and uses thereof
JP6279065B2 (en) * 2013-03-13 2018-02-14 サノフイ Composition comprising anti-CD38 antibody and carfilzomib
EP3027648A1 (en) * 2013-08-02 2016-06-08 Institut National de la Santé et de la Recherche Médicale (INSERM) Anti-claudin 1 antibodies and uses thereof
JP2016536314A (en) * 2013-10-31 2016-11-24 サノフイ Specific anti-CD38 antibodies for treating human cancer
UA120748C2 (en) * 2013-10-31 2020-02-10 Санофі Specific anti-cd38 antibodies for treating human cancers
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2016022589A2 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California Methods for treating multiple myeloma
KR102586588B1 (en) 2014-09-09 2023-10-06 얀센 바이오테크 인코포레이티드 Combination therapies with anti-cd38 antibodies
SG11201704390PA (en) 2014-12-04 2017-06-29 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemia
UA124143C2 (en) 2015-05-20 2021-07-28 Янссен Байотек, Інк. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
CN107708734B (en) 2015-06-22 2022-01-11 詹森生物科技公司 Combination therapy of heme malignancies with anti-CD 38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
PT3370770T (en) 2015-11-03 2021-02-22 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
US11780930B2 (en) 2017-06-08 2023-10-10 Black Belt Therapeutics Limited CD38 modulating antibody
US11236173B2 (en) 2017-08-16 2022-02-01 Black Belt Therapeutics Limited CD38 antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
AU2018359527A1 (en) 2017-10-31 2020-05-07 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
KR20220159947A (en) 2019-12-05 2022-12-05 사노피-아벤티스 유.에스. 엘엘씨 Formulations of Anti-CD38 Antibodies for Subcutaneous Administration

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3032585A (en) 1954-12-03 1962-05-01 Nat Res Dev Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
US3116282A (en) 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
KR100654645B1 (en) 1995-04-27 2007-04-04 아브게닉스, 인크. Human Antibodies from Immunized Genomous
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE549918T1 (en) 1996-12-03 2012-04-15 Amgen Fremont Inc HUMAN ANTIBODIES THAT EXPRESSLY BIND HUMAN TNF ALPHA
EP0970126B1 (en) 1997-04-14 2001-04-18 Micromet AG Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
DE19826517B4 (en) 1998-06-15 2006-03-23 Baxter Healthcare S.A. Process for the preparation of film-coated tablets with cyclophosphamide as active ingredient and cyclophosphamide film-coated tablet produced therefrom
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
GB0221574D0 (en) 2002-09-17 2002-10-23 Isis Innovation Treatments
BRPI0507489A (en) 2004-02-06 2007-07-10 Morphosys Ag anti-cd38 human antibodies and their uses
JP4912597B2 (en) 2004-07-13 2012-04-11 パナソニック株式会社 Liquid crystal display
US20080057070A1 (en) 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
EP2567976B1 (en) * 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
JP5476122B2 (en) * 2006-09-26 2014-04-23 ゲンマブ エー／エス Combination treatment of CD38 expressing tumor
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR101667944B1 (en) 2007-08-29 2016-10-20 사노피 Humanized anti-CXCR5 antibodies, derivatives thereof and their uses
US8551485B2 (en) 2008-01-23 2013-10-08 Xencor, Inc. Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
ES2617446T3 (en) * 2010-09-27 2017-06-19 Morphosys Ag Anti-cd38 and lenalidomide or bortezomib antibody for the treatment of multiple myeloma and nhl
UA112170C2 (en) 2010-12-10 2016-08-10 Санофі ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB
US8542056B2 (en) * 2010-12-27 2013-09-24 Stmicroelectronics S.Rl. High voltage transmission switch, namely for ultrasound applications
UA118255C2 (en) 2012-12-07 2018-12-26 Санофі Compositions comprising anti-cd38 antibodies and lenalidomide
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
JP6279065B2 (en) 2013-03-13 2018-02-14 サノフイ Composition comprising anti-CD38 antibody and carfilzomib
JP2016536314A (en) 2013-10-31 2016-11-24 サノフイ Specific anti-CD38 antibodies for treating human cancer

Also Published As

Publication number Publication date
DOP2013000132A (en) 2013-09-30
SI2648747T1 (en) 2019-04-30
UA112170C2 (en) 2016-08-10
KR20130130774A (en) 2013-12-02
EA026406B1 (en) 2017-04-28
WO2012076663A1 (en) 2012-06-14
CY1121179T1 (en) 2020-05-29
AU2011340472A1 (en) 2013-05-02
EA201390850A1 (en) 2013-12-30
MA34816B1 (en) 2014-01-02
RS57997B1 (en) 2019-01-31
HRP20181787T1 (en) 2018-12-28
JP6177133B2 (en) 2017-08-09
EA201692047A1 (en) 2017-06-30
PT2648747T (en) 2018-11-21
PE20140004A1 (en) 2014-01-23
CO6801634A2 (en) 2013-11-29
GT201300147A (en) 2017-12-15
UY33791A (en) 2012-07-31
US20140186337A1 (en) 2014-07-03
TW201307392A (en) 2013-02-16
CN103282050A (en) 2013-09-04
HUE039893T2 (en) 2019-02-28
EP2648747B1 (en) 2018-08-08
KR101905208B1 (en) 2018-10-05
CA2820382C (en) 2020-08-18
PL2648747T3 (en) 2019-01-31
AU2011340472B2 (en) 2015-02-12
ES2694784T3 (en) 2018-12-27
CN103282050B (en) 2016-09-07
SG191059A1 (en) 2013-08-30
MY165109A (en) 2018-02-28
CL2013001670A1 (en) 2014-02-28
AR084196A1 (en) 2013-04-24
BR112013014370B1 (en) 2020-12-01
ZA201304845B (en) 2014-09-25
MX2013006566A (en) 2013-08-26
JP2014502280A (en) 2014-01-30
ECSP13012669A (en) 2013-08-30
TWI596116B (en) 2017-08-21
TR201816532T4 (en) 2018-11-21
DK2648747T3 (en) 2018-12-03
NZ612055A (en) 2014-12-24
IL226756B (en) 2020-06-30
CN106334187A (en) 2017-01-18
EP2648747A1 (en) 2013-10-16
NI201300050A (en) 2013-08-01
BR112013014370A2 (en) 2017-05-30
MX345257B (en) 2017-01-23
CR20130270A (en) 2013-09-03
LT2648747T (en) 2018-11-26
CN106334187B (en) 2021-02-12
EP3412311A1 (en) 2018-12-12
CA2820382A1 (en) 2012-06-14
US9314522B2 (en) 2016-04-19
TN2013000245A1 (en) 2014-11-10

Similar Documents

Publication Publication Date Title
HRP20181787T1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
HK1216540A1 (en) Cd20 antibodies and uses thereof cd20
HK1164153A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine cd38
HK1164154A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide cd38
HK1200468A1 (en) Anti-erbb3 antibodies and uses thereof -erbb3
IL213118A0 (en) Antitumor combinations containing antibodies recognizing specifically cd38 andcyclophosphamide
PL2580243T3 (en) Antibodies against human cd38
HK1164165A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan cd38
IL225545A0 (en) Tumor specific antibodies and uses therefor
EP2788377A4 (en) Her3 antibodies and uses thereof
HK1205523A1 (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof ---1(big-et-1)
EP2861623A4 (en) Novel antibody specific for clec14a and uses thereof
HUE048721T2 (en) Antibodies against human cd38
GB201019435D0 (en) Carrier and blank therefor
GB201001499D0 (en) Carrier and blank therefor